Among these, Ab-31 demonstrated potent in vitro activity at inhibiting TGFβ-induced αSMA expression in lung fibroblasts derived from IPF patients than did MK-0429 and another benchmarking molecule. This evidence concerns the gene ACTA1 and idiopathic pulmonary fibrosis.